Amgen and its partner Allergan announced Friday that their ABP 980, a trastuzumab biosimilar referencing Herceptin, has gained a positive opinion for marketing from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Amgen and its partner Allergan announced Friday that their ABP 980, a trastuzumab biosimilar referencing Herceptin, has gained a positive opinion for marketing (for all indications of the reference Herceptin) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Amgen—Allergan’s marketing application for ABP 980 was supported by analytical, pharmacokinetic, and clinical data, as well as pharmacology and toxicology data. The phase 3 comparative efficacy, safety, and immunogenicity study was conducted in adult patients with HER2-positive early breast cancer.
Before the companies are granted a final clearance to market the drug in the European Union, the European Commission (EC) will review the CHMP opinion. If the EC grants a centralized marketing authorization, the biosimilar may be sold in the 28 member states of the European Union. Members of the European Economic Area will make corresponding decisions on the basis of the EC’s verdict.
If approved, the biosimilar will compete with Celltrion’s Herzuma, a trastuzumab biosimilar that will be distributed by Mundipharma in 7 EU nations, and Samsung Bioepis’ Ontruzant, another biosimilar of the reference Herceptin, that has recently launched by Merck—operating under the trade name MSD—in the United Kingdom.
Meanwhile, in the United States, patients await the arrival of a biosimilar trastuzumab. Biocon, sponsor of Ogivri, the only FDA-approved trastuzumab biosimilar to date, has not yet announced a launch date for its product, and Celltrion and Teva’s CT-P6 and Pfizer’s PF-05280014 are both awaiting regulatory decisions by the FDA.
Amgen and Allergan have also developed the FDA- and EMA-approved adalimumab (Humira) biosimilar that will eventually be marketed as Amjevita and Amgevita, as well as a bevacizumab (Avastin) biosimilar that will eventually enter the market as Mvasi. The partnership is also developing ABP 798, a biosimilar rituximab; ABP 710, a biosimilar infliximab; and ABP 494, a biosimilar cetuximab. Amgen reports that it has another 3 undisclosed biosimilar products under development.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.